EP0958364A4 - IMMUNOTHERAPY AND IMPROVED Vaccines - Google Patents

IMMUNOTHERAPY AND IMPROVED Vaccines

Info

Publication number
EP0958364A4
EP0958364A4 EP97912961A EP97912961A EP0958364A4 EP 0958364 A4 EP0958364 A4 EP 0958364A4 EP 97912961 A EP97912961 A EP 97912961A EP 97912961 A EP97912961 A EP 97912961A EP 0958364 A4 EP0958364 A4 EP 0958364A4
Authority
EP
European Patent Office
Prior art keywords
immunotherapy
improved vaccines
vaccines
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97912961A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0958364A1 (en
Inventor
Jong J Kim
Velpandi Ayyavoo
Bin Wang
Jean D Boyer
David B Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of EP0958364A1 publication Critical patent/EP0958364A1/en
Publication of EP0958364A4 publication Critical patent/EP0958364A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
EP97912961A 1996-10-23 1997-10-23 IMMUNOTHERAPY AND IMPROVED Vaccines Withdrawn EP0958364A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2861396P 1996-10-23 1996-10-23
US2861P 1996-10-23
PCT/US1997/019502 WO1998017799A1 (en) 1996-10-23 1997-10-23 Immunotherapy and improved vaccines

Publications (2)

Publication Number Publication Date
EP0958364A1 EP0958364A1 (en) 1999-11-24
EP0958364A4 true EP0958364A4 (en) 2001-10-31

Family

ID=21844431

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97912961A Withdrawn EP0958364A4 (en) 1996-10-23 1997-10-23 IMMUNOTHERAPY AND IMPROVED Vaccines

Country Status (8)

Country Link
EP (1) EP0958364A4 (ko)
JP (3) JP2001507216A (ko)
KR (4) KR20070108418A (ko)
CN (2) CN1868545A (ko)
AU (1) AU729579B2 (ko)
BR (1) BR9712852A (ko)
CA (3) CA2745736C (ko)
WO (1) WO1998017799A1 (ko)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002301344B2 (en) * 1998-05-06 2005-01-13 Association Francais Contre Les Myopathies Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
US6528312B1 (en) 1998-05-06 2003-03-04 Transgene S.A. Use of G-actin for improving transfection of a polynucleotide into a cell
CA2328059A1 (en) * 1998-05-07 1999-11-11 Akzo Nobel Nv Use of interleukin-18 as vaccine adjuvant
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
IL144845A0 (en) * 1999-03-03 2002-06-30 Univ Pennsylvania Vaccines and gene therapy compositions and methods of making and using the same
SK14832001A3 (sk) 1999-04-23 2003-02-04 Pharmexa A/S Analóg interleukínu 5, fragment nukleovej kyseliny, vektor, bunka, prípravky a použitie
HUP0201220A3 (en) * 1999-05-13 2004-07-28 Wyeth Holdings Corp Madison Adjuvant combination formulations
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
WO2001048018A1 (en) * 1999-12-27 2001-07-05 University Of Manitoba Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic escherichia coli and other pathogens
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US7754201B2 (en) 2000-06-02 2010-07-13 GenPhar, Inc Method of vaccination through serotype rotation
US7092633B2 (en) 2000-11-14 2006-08-15 University Of Texas System Board Of Regents System and method for configuring optical circuits
JP2002221520A (ja) * 2001-01-29 2002-08-09 Sumitomo Chem Co Ltd 免疫型の予測方法
ATE430807T1 (de) * 2001-03-27 2009-05-15 Univ Saskatchewan Verfahren zur kultivierung von circovirus
KR20030012199A (ko) * 2001-07-31 2003-02-12 (주)지노첵 사이토카인 유전자를 유효성분으로 포함하는 ｄｎａ 백신
EP1465928B1 (en) 2002-01-17 2009-09-30 Polymun Scientific Immunbiologische Forschung GmbH Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
GB0223696D0 (en) * 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
CN1756845A (zh) 2002-11-12 2006-04-05 A·B·德塞罗斯 腺病毒载体疫苗
US8663622B2 (en) 2002-12-16 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant vaccine viruses expressing IL-15 and methods using the same
US20040146486A1 (en) * 2003-01-24 2004-07-29 Juan Sun Hybrid vector system for use as a vaccine
WO2004069272A2 (en) * 2003-02-05 2004-08-19 Movecare Ltd Adjuvant combination for use in the immunization of a mamal comprising il2 and il12
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
CA2544946A1 (en) 2003-11-24 2005-03-06 Sidney Kimmel Cancer Center Mucin antigen vaccine
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
TWI379839B (en) 2003-12-17 2012-12-21 Wyeth Llc Aβ immunogenic peptide carrier conjugates and methods of producing same
WO2005058940A2 (en) 2003-12-17 2005-06-30 Wyeth Immunogenic peptide carrier conjugates and methods of producing same
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CN101228272A (zh) * 2005-04-20 2008-07-23 生物载体株式会社 用于治疗阿尔茨海默病的具有较高安全性的经鼻腔内给药基因疫苗
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
EP2395077A1 (en) 2006-11-03 2011-12-14 Wyeth LLC Glycolysis-inhibiting substances in cell culture
WO2008109410A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
EP2265715B1 (en) 2008-04-04 2016-12-28 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same
WO2010051820A1 (en) * 2008-11-10 2010-05-14 Aarhus Universitet Multiplexed cytokine vaccination
WO2010126766A1 (en) 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
US20130197612A1 (en) * 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
CN102370979B (zh) * 2011-10-10 2013-05-01 中国人民解放军第四军医大学 一种针对人TNF-α分子的自体疫苗的构建方法
EP2875041A2 (en) 2012-07-19 2015-05-27 Zoetis LLC Bovine influenza c virus compositions
WO2014018724A1 (en) 2012-07-27 2014-01-30 Zoetis Llc Tick toxin compositions
US20160008449A1 (en) 2013-03-15 2016-01-14 Zoetis Services Llc CROSS-PROTECTION OF BOVINES AGAINST B. trehalosi INFECTION BY A MULTI-VALENT VACCINE
AU2014229561B2 (en) 2013-03-15 2018-06-07 Keith Alan Charlton Self-assembling synthetic proteins
EA034110B1 (ru) * 2013-03-15 2019-12-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Противораковые вакцины и способы лечения с их применением
ES2933623T3 (es) 2015-08-14 2023-02-10 Zoetis Services Llc Composiciones de Mycoplasma Bovis
WO2017123201A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
CN110996975A (zh) 2017-04-13 2020-04-10 森迪生物科学公司 组合癌症免疫疗法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
TW202035685A (zh) 2018-10-17 2020-10-01 美商聖堤生物科技股份有限公司 組合癌症免疫療法
EP3897691A4 (en) * 2018-12-21 2022-08-31 The Regents of the University of California IL-10 VACCINES AND THEIR USES
CN110170049B (zh) * 2019-06-01 2023-07-04 山西农业大学 一种用于鸡球虫病活疫苗的细胞因子基因佐剂
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984001575A1 (en) * 1982-10-11 1984-04-26 Nat Biolog Standards Board Polypeptides useful in vaccination against enteroviruses
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275300B1 (en) * 1986-08-01 1996-01-03 Commonwealth Scientific And Industrial Research Organisation Recombinant vaccine
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5238823A (en) * 1990-08-22 1993-08-24 Veterinary Infectious Disease Organization Interleukin-2-leukotoxin gene fusions and uses thereof
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984001575A1 (en) * 1982-10-11 1984-04-26 Nat Biolog Standards Board Polypeptides useful in vaccination against enteroviruses
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRONTE V ET AL: "IL-2 ENHANCES THE FUNCTION OF RECOMBINANT POXVIRUS-BASED VACCINES IN THE TREATMENT OF ESTABLISHED PULMONARY METASTASES", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 154, no. 10, 15 May 1995 (1995-05-15), pages 5282 - 5292, XP002030630, ISSN: 0022-1767 *
CHOW YEN-HUNG ET AL: "Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.", JOURNAL OF VIROLOGY, vol. 71, no. 1, 1997, pages 169 - 178, XP002176596, ISSN: 0022-538X *
GREENBERGER MJ ET AL.,: "Il-12 gene therapy protects mice in lethal Klebsiella pneumonia", J IMMUNOL., vol. 157, no. 7, 1 October 1997 (1997-10-01), XP001015488 *
IRVINE K R ET AL: "CYTOKINE ENHANCEMENT OF DNA IMMUNIZATION LEADS TO EFFECTIVE TREATMENT OF ESTABLISHED PULMONARY METASTASES", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 156, 1996, pages 238 - 245, XP002030631, ISSN: 0022-1767 *
LIEU FRANCIS H L ET AL: "Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: Implications for immune gene therapy.", CANCER GENE THERAPY, vol. 4, no. 3, 1997, pages 167 - 175, XP001019756, ISSN: 0929-1903 *
See also references of WO9817799A1 *
XIANG Z ET AL: "MANIPULATION OF THE IMMUNE RESP0NSE TO A PLASMID-ENCODED VIRAL ANTIGEN BY COINOCULATION WITH PLASMIDS EXPRESSING CYTOKINES", IMMUNITY, CELL PRESS, US, vol. 2, no. 2, 1 February 1995 (1995-02-01), pages 129 - 135, XP000670098, ISSN: 1074-7613 *

Also Published As

Publication number Publication date
JP2009232860A (ja) 2009-10-15
CA2751712A1 (en) 1998-04-30
AU729579B2 (en) 2001-02-01
KR20050008860A (ko) 2005-01-21
BR9712852A (pt) 1999-11-16
CA2745736C (en) 2016-11-22
JP2008194046A (ja) 2008-08-28
CA2269074A1 (en) 1998-04-30
KR20070108418A (ko) 2007-11-09
WO1998017799A1 (en) 1998-04-30
CN1868545A (zh) 2006-11-29
EP0958364A1 (en) 1999-11-24
KR20050053796A (ko) 2005-06-08
CA2745736A1 (en) 1998-04-30
CA2751712C (en) 2016-11-22
KR100629835B1 (ko) 2006-09-29
CN1242045A (zh) 2000-01-19
JP2001507216A (ja) 2001-06-05
KR100780158B1 (ko) 2007-11-27
KR20000052710A (ko) 2000-08-25
AU5002297A (en) 1998-05-15
CN1257976C (zh) 2006-05-31

Similar Documents

Publication Publication Date Title
EP0958364A4 (en) IMMUNOTHERAPY AND IMPROVED Vaccines
HUP9904549A3 (en) Vaccines
EP1021185A4 (en) DIHYDROPYRIMIDINE AND ITS USES.
EP0958373A4 (en) Vaccines.
HUP9700446A3 (en) Oilsuspension-concentrate and using thereof
GB9410922D0 (en) Vaccines
HUP9701586A3 (en) Improved inactivated vaccines
EP0876157A4 (en) METHODS AND COMPOSITIONS FOR PASSIVE IMMUNOTHERAPY
PL332631A1 (en) Spray-crystallised products and associated methods
ZA9711565B (en) Vaccine
EP0888126A4 (en) ANTI-IDIOTYPICAL ANTIBODY VACCINE
PL331523A1 (en) Azolotrizines and azolopyrimidines
GB2331521B (en) Vaccine preparations
PL328334A1 (en) Preparation and application thereof
GB9625968D0 (en) Vaccine
ZA973824B (en) Vaccines
GB9602617D0 (en) Vaccines
GB9604595D0 (en) Vaccines
GB9605229D0 (en) Vaccines
GB9614182D0 (en) Vaccines
GB9626882D0 (en) Vaccines
GB9606032D0 (en) Vaccines
GB9604596D0 (en) Vaccines
GB9406708D0 (en) Vaccines
ZA9711530B (en) Veterinary vaccines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990505

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/18 A, 7A 61K 48/00 B, 7A 61K 31/00 B, 7C 12N 15/86 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010918

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20020923

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/54 20060101ALI20110211BHEP

Ipc: A61K 48/00 20060101ALI20110211BHEP

Ipc: C12N 15/19 20060101AFI20110211BHEP

RTI1 Title (correction)

Free format text: ENHANCEMENT OF DNA IMMUNIZATION BY CO-EXPRESSION OF IL-12 SUBUNITS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110727